Oxetanes as versatile elements in drug discovery and synthesis

Angewandte Chemie - International Edition

Volumn 49, Issue 48, 2010, Pages 9052-9067

  Burkhard, Johannes A ^a   Wuitschik, Georg ^a   Rogers Evans, Mark ^b   Müller, Klaus ^b   Carreira, Erick M ^a  

^a ETH ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

drug discovery; heterocyclic compounds; oxetanes; spiro compounds

Indexed keywords

BIOCHEMICAL PROPERTIES; CHEMICAL TRANSFORMATIONS; DRUG DISCOVERY; HETEROCYCLIC COMPOUND; MEDICINAL CHEMISTRY; MOLECULAR ARCHITECTURE; MOLECULAR SCAFFOLDS; OXETANES; PHARMACEUTICAL AGENTS; SPIRO COMPOUNDS; STEREOCENTERS;

ORGANIC COMPOUNDS; SCAFFOLDS;

ORGANIC LIGHT EMITTING DIODES (OLED);

DRUG; ETHER DERIVATIVE; OXETANE;

CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; REVIEW;

DRUG DESIGN; DRUG DISCOVERY; ETHERS, CYCLIC; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 78649550137     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.200907155     Document Type: Review

References (148)

1. M. Reboul, Ann. Chim. 1878, 14, 496.
2. G. Wuitschik, M. Rogers-Evans, K. Müller, H. Fischer, B. Wagner, F. Schuler, L. Polonchuk, E. M. Carreira, Angew. Chem. 2006, 118, 7900-7903
3. Angew. Chem. Int. Ed. 2006, 45, 7736-7739
4. G. Wuitschik, M. Rogers-Evans, A. Buckl, M. Bernasconi, M. Märki, T. Godel, H. Fischer, B. Wagner, I. Parrilla, F. Schuler, J. Schneider, A. Alker, W. B. Schweizer, K. Müller, E. M. Carreira, Angew. Chem. 2008, 120, 4588-4591
5. Angew. Chem. Int. Ed. 2008, 47, 4512-4515
6. G. Wuitschik, E. M. Carreira, M. Rogers-Evans, K. Müller, in Process Chem. Pharm. Ind. (Eds.:, K. Gadamasetti, T. Braish,), CRC, Boca Raton, 2008, pp. 217-229
7. details can be found in: G. Wuitschik, PhD Thesis, ETH Zurich (Zurich), 2008, DOI
8. G. Wuischik, E. M. Carreira, B. Wagner, H. Fischer, I. Parrilla, F. Schuler, M. Rogers-Evans, K. Müller, J. Med. Chem. 2010, 53, 3227-3246.
9. Selected examples from the extensive recent patent literature
10. T. Siu, J. Young, M. Altman, A. Northrup, M. Katcher, E. Sathyajith, E. Peterson, M. Childers, (Merck), US 20100197634, 2010
11. W. A. Carroll, M. J. Dart, J. M. Frost, S. P. Latshaw, T. Kolasa, T. Li, S. Peddi, B. Liu, A. Perez-Medrano, M. Patel, X. Wang, D. W. Nelson (Abbott Laboratories), WO 2010033543, 2010
12. H. Suzuki, T. Fujimoto, T. Yamamoto, (Takeda), WO 2010087467, 2010
13. D. Kadereit, M. Schaefer, W. Czechtizky, (Sanofi-Aventis), WO 2010006704, 2010
14. P. Bergeron, F. Cohen, A. Estrada, M. F. T. Koehler, K. H. L. Lau, C. Ly, J. P. Lyssikatos, D. F. Ortwine, Z. Pei, X. Zhao, (Genentech), WO 2010014939, 2010
15. R. Albert, N. G. Cooke, F. Zecri, I. Lewis, (Novartis), WO 2009068682, 2009
16. B. C. Barlaam, C. E. Chuaqui, B. Delouvrie, G. Ouvry, T. Wang, J. J. G. Winter, (Astrazeneca), WO 2009024825, 2009
17. H. Knust, M. Nettekoven, E. Pinard, O. Roche, M. Rogers-Evans, (Hoffmann-La Roche), WO 2009016087, 2009.
18. Prous Science Integrity, search in May 2008.
19. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon, A. T. McPhail, J. Am. Chem. Soc. 1971, 93, 2325-2327.
20. The Chemistry and Pharmacology of Taxol and its Derivatives (Ed.:, V. Farina,), Pharmacochem. Libr., 1995, p. 22.
21. T. C. Boge, M. Hepperle, D. G. Vander Velde, C. W. Gunn, G. L. Grunewald, G. I. Georg, Bioorg. Med. Chem. Lett. 1999, 9, 3041-3046.
22. M. Wang, B. Cornett, J. Nettles, D. C. Liotta, J. P. Snyder, J. Org. Chem. 2000, 65, 1059-1068.
23. A. A. L. Gunatilaka, F. D. Ramdayal, M. H. Sarragiotto, D. G. I. Kingston, D. L. Sackett, E. Hamel, J. Org. Chem. 1999, 64, 2694-2703
24. R. Marder-Karsenti, J. Dubois, L. Bricard, D. Guenard, F. Gueritte-Voegelein, J. Org. Chem. 1997, 62, 6631-6637.
25. N. Shimada, S. Hasegawa, T. Harada, T. Tomisawa, A. Fujii, T. Takita, J. Antibiot. 1986, 39, 1623-1625.
26. For a review on its biological activity, see H. Hoshino, N. Shimizu, N. Shimada, T. Takita, T. Takeuchi, J. Antibiot. 1987, 40, 1077-1078
27. J. Seki, N. Shimada, K. Takahashi, T. Takita, T. Takeuchi, H. Hoshino, Antimicrob. Agents Chemother. 1989, 33, 773-775. Norbeck published in 1988 the first total synthesis of (-)-Oxetanocin A
28. D. W. Norbeck, J. B. Kramer, J. Am. Chem. Soc. 1988, 110, 7217-7218.
29. New Synthetic Routes to Prostaglandins and Thromboxanes (Eds.:, S. M. Roberts, F. Scheinmann,), Academic Press, London, 1982.
30. J. M. Huang, R. Yokoyama, C. S. Yang, Y. Fukuyama, Tetrahedron Lett. 2000, 41, 6111-6114.
31. V. B. Birman, S. J. Danishefsky, J. Am. Chem. Soc. 2002, 124, 2080-2081
32. G. Mehta, S. R. Singh, Angew. Chem. 2006, 118, 967-969
33. Angew. Chem. Int. Ed. 2006, 45, 953-955
34. S. J. Danishefsky, Asymm. Synth. 2007, 251-255
35. M. Inoue, N. Lee, S. Kasuya, T. Sato, M. Hirama, M. Moriyama, Y. Fukuyama, J. Org. Chem. 2007, 72, 3065-3075
36. W. He, J. Huang, X. Sun, A. J. Frontier, J. Am. Chem. Soc. 2008, 130, 300-308.
37. C. Li, D. Lee, T. N. Graf, S. S. Phifer, Y. Nakanishi, J. P. Burgess, S. Riswan, F. M. Setyowati, A. M. Saribi, D. D. Soejarto, N. R. Farnsworth, J. O. Falkinham, D. J. Kroll, A. D. Kinghorn, M. C. Wani, N. H. Oberlies, Org. Lett. 2005, 7, 5709-5712.
38. S. Omura, M. Murata, N. Imamura, Y. Iwai, H. Tanaka, A. Furusaki, T. Matsumoto, J. Antibiot. 1984, 37, 1324-1332.
39. Q. B. Han, J. X. Zhang, Y. Lu, Y. S. Wu, Q. T. Zheng, H. D. Sun, Planta Med. 2004, 70, 581-584. A derivative in which the oxetane ring was cleaved methanolytically showed no cytotoxicity.
40. K. C. Pullaiah, R. K. Surapaneni, C. B. Rao, K. F. Albizati, B. W. Sullivan, D. J. Faulkner, C. H. He, J. Clardy, J. Org. Chem. 1985, 50, 3665-3666.
41. J. Reinecke, H. M. R. Hoffmann, Chem. Eur. J. 1995, 1, 368-373
42. K. A. Marshall, A. K. Mapp, C. H. Heathcock, J. Org. Chem. 1996, 61, 9135-9145
43. J. Wittenberg, W. Beil, H. M. R. Hoffmann, Tetrahedron Lett. 1998, 39, 8259-8262
44. S. Proemmel, R. Wartchow, H. M. R. Hoffmann, Tetrahedron 2002, 58, 6199-6206.
45. J. Loh, R. W. Carlson, W. S. York, G. Stacey, Proc. Natl. Acad. Sci. USA 2002, 99, 14446-14451.
46. G. Holan, Nature 1971, 232, 644-647.
47. W. Meyer, (Ciba-Geigy AG), EP 92-810027, 1992.
48. M. K. Koeppe, H. M. Brown, Agro Food Ind. Hi-Tech 1995, 6, 9-14.
49. Personal communication, Syngenta AG, 2008.
50. S. B. Soloway, P. Vogel, C. H. Aubin le Drian, J. E. Powell, (Du Pont de Nemours, E. I., and Co.), US 86-916334, 1986.
51. M. Berthelot, F. Besseau, C. Laurence, Eur. J. Org. Chem. 1998, 925-931. The equilibrium concentrations were determined by measuring the absorbances of the O-H stretch of 4-fluorophenol at different initial base concentrations.
52. L. Bellon, R. W. Taft, J. L. M. Abboud, J. Org. Chem. 1980, 45, 1166-1168.
53. R. West, L. S. Whatley, M. K. T. Lee, D. L. Powell, J. Am. Chem. Soc. 1964, 86, 3227-3229
54. E. Lippert, H. Prigge, Justus Liebigs Ann. Chem. 1962, 659, 81-89.
55. M. Brandon, M. Tamres, S. Searles, J. Am. Chem. Soc. 1960, 82, 2129-2134.
56. H. H. Sisler, P. E. Perkins, J. Am. Chem. Soc. 1956, 78, 1135-1136.
57. For related studies with a variety of carbonyl compounds, see F. Besseau, M. Lucon, C. Laurence, M. Berthelot, J. Chem. Soc. Perkin Trans. 2 1998, 101-107
58. F. Besseau, C. Laurence, M. Berthelot, J. Chem. Soc. Perkin Trans. 2 1994, 485-489
59. J. Y. Le Questel, C. Laurence, A. Lachkar, M. Helbert, M. Berthelot, J. Chem. Soc. Perkin Trans. 2 1992, 2091-2094.
60. G. M. Bennett, W. G. Philip, J. Chem. Soc. 1928, 1937-1942.
61. W. D. Gwinn, Discuss. Faraday Soc. 1955, 19, 43-51
62. J. Fernandez, R. J. Myers, W. D. Gwinn, J. Chem. Phys. 1955, 23, 758-759. The upper boundary for puckering of the oxetane ring at ambient temperature was determined to be 0°20′.
63. Selected reviews J. A. Porco, S. L. Schreiber, in Comprehensive Organic Synthesis, Vol. 5 (Eds.:, B. M. Trost, I. Fleming,), Pergamon, Oxford, 1991, pp. 151-192
64. T. Bach, Synthesis 1998, 683-703.
65. For previous reviews about oxetanes, see S. Searles, in The Chemistry of Heterocyclic Compounds, Vol. 19-2 (Ed.:, A. Weissberger,), Wiley-Interscience, New York, 1964, pp. 983-1068
66. S. Searles, in Comprehensive Heterocyclic Chemistry, Vol. 7 (Eds.:, A. R. Katritzky, C. W. Rees,), Pergamon, Oxford, 1984, pp. 363-402.
67. K. Soai, S. Niwa, T. Yamanoi, H. Hikima, M. Ishizaki, J. Chem. Soc. Chem. Commun. 1986, 1018-1019.
68. J. W. Bode, E. M. Carreira, J. Org. Chem. 2001, 66, 6410-6424.
69. S. C. Welch, A. S. C. P. Rao, J. Am. Chem. Soc. 1979, 101, 6135-6136
70. S. C. Welch, A. S. C. P. Rao, J. T. Lyon, J. M. Assercq, J. Am. Chem. Soc. 1983, 105, 252-257.
71. K. Okuma, Y. Tanaka, S. Kaji, H. Ohta, J. Org. Chem. 1983, 48, 5133-5134; for an expansion of the substrate scope, see
72. A. O. Fitton, J. Hill, D. E. Jane, R. Millar, Synthesis 1987, 1140-1142.
73. T. Sone, G. Lu, S. Matsunaga, M. Shibasaki, Angew. Chem. 2009, 121, 1705-1708
74. Angew. Chem. Int. Ed. 2009, 48, 1677-1680.
75. T. Bach, K. Jödicke, K. Kather, J. Hecht, Angew. Chem. 1995, 107, 2455-2457
76. Angew. Chem. Int. Ed. Engl. 1995, 34, 2271-2273
77. T. Bach, K. Jödicke, K. Kather, R. Fröhlich, J. Am. Chem. Soc. 1997, 119, 2437-2445.
78. M. A. J. Duncton, M. A. Estiarte, D. Tan, C. Kaub, D. J. R. O'Mahony, R. J. Johnson, M. Cox, W. T. Edwards, M. Wan, J. Kincaid, M. G. Kelly, Org. Lett. 2008, 10, 3259-3262.
79. F. González-Bobes, G. C. Fu, J. Am. Chem. Soc. 2006, 128, 5360-5361.
80. M. A. J. Duncton, M. A. Estiarte, R. J. Johnson, M. Cox, D. J. R. O'Mahony, W. T. Edwards, M. G. Kelly, J. Org. Chem. 2009, 74, 6354-6357.
81. G. H. Berezin, (Du Pont de Nemours, E.I., and Co.), US 3297719, 1967.
82. J. R. Marshall, J. Walker, J. Chem. Soc. 1952, 467-475.
83. J. A. Wojtowicz, R. J. Polak, J. Org. Chem. 1973, 38, 2061-2066
84. A. P. Kozikowski, A. H. Fauq, Synlett 1991, 783-784.
85. P. Yates, A. G. Szabo, Tetrahedron Lett. 1965, 6, 485-488
86. G. H. Berezin, (Du Pont de Nemours, E. I., and Co.), US 3449369, 1969
87. M. D. T. Moldes, G. Costantino, M. Marinozzi, R. Pellicciari, Farmaco 2001, 56, 609-613. For a review about the preparation of oxetan-3-ones and their chemistry, see
88. Y. Dejaegher, N. M. Kuz'menok, A. M. Zvonok, N. De Kimpe, Chem. Rev. 2002, 102, 29-60.
89. E. Bacqué, J. M. Paris, S. Le Bitoux, Synth. Commun. 1995, 25, 803-812.
90. A. R. Abdun-Nur, C. H. Issidorides, J. Org. Chem. 1962, 27, 67-70.
91. P. J. Hamzik, J. D. Brubaker, Org. Lett. 2010, 12, 1116-1119.
92. B. Ringnér, S. Sunner, H. Watanabe, Acta Chem. Scand. 1971, 25, 141
93. H. K. Eigenmann, D. M. Golden, S. W. Benson, J. Phys. Chem. 1973, 77, 1687-1691.
94. J. G. Pritchard, F. A. Long, J. Am. Chem. Soc. 1958, 80, 4162-4165. For kinetic studies on the mechanism of acid-catalyzed ring opening of oxetane, see
95. M. Lajunen, J.-M. Koskinen, Acta Chem. Scand. 1994, 48, 788-791.
96. J. L. Wolk, M. Sprecher, H. Basch, S. Hoz, Org. Biomol. Chem. 2004, 2, 1065-1069
97. J. L. Wolk, T. Hoz, H. Basch, S. Hoz, J. Org. Chem. 2001, 66, 915-918
98. A. Sella, H. Basch, S. Hoz, J. Am. Chem. Soc. 1996, 118, 416-420. Hoz and co-workers reject previously made claims
99. H. D. Banks, J. Org. Chem. 2003, 68, 2639-2644) that the reactivity difference can be traced back to different degrees of stabilization of the reacting center's partial positive charge by the leaving alkoxide.
100. D. Sawicka, K. N. Houk, J. Mol. Model. 2000, 6, 158-165.
101. C. G. Derick, D. W. Bissell, J. Am. Chem. Soc. 1916, 38, 2478-2486.
102. J. Burkhard, E. M. Carreira, Org. Lett. 2008, 10, 3525-3526
103. J. A. Burkhard, B. Wagner, H. Fischer, F. Schuler, K. Müller, E. M. Carreira, Angew. Chem. 2010, 122, 3603-3606
104. Angew. Chem. Int. Ed. 2010, 49, 3524-3527.
105. J. C. Mullis, W. P. Weber, J. Org. Chem. 1982, 47, 2873-2875.
106. S. A. Carr, W. P. Weber, J. Org. Chem. 1985, 50, 2782-2785.
107. M. Yamaguchi, Y. Nobayashi, I. Hirao, Tetrahedron Lett. 1983, 24, 5121-5122
108. M. Yamaguchi, Y. Nobayashi, I. Hirao, Tetrahedron 1984, 40, 4261-4266.
109. M. Mizuno, M. Kanai, A. Iida, K. Tomioka, Tetrahedron: Asymmetry 1996, 7, 2483-2484
110. M. Mizuno, M. Kanai, A. Iida, K. Tomioka, Tetrahedron 1997, 53, 10699-10708.
111. F. Bertolini, S. Crotti, V. Di Bussolo, F. Macchia, M. Pineschi, J. Org. Chem. 2008, 73, 8998-9007.
112. T. Bach, K. Kather, O. Kramer, J. Org. Chem. 1998, 63, 1910-1918, and references therein.
113. R. N. Loy, E. N. Jacobsen, J. Am. Chem. Soc. 2009, 131, 2786-2787.
114. L. P. C. Nielsen, C. P. Stevenson, D. G. Blackmond, E. N. Jacobsen, J. Am. Chem. Soc. 2004, 126, 1360-1362.
115. H. Nozaki, S. Moriuti, H. Takaya, R. Noyori, Tetrahedron Lett. 1966, 7, 5239-5244
116. H. Nozaki, H. Takaya, S. Moriuti, R. Noyori, Tetrahedron 1968, 24, 3655-3669.
117. K. Ito, T. Katsuki, Chem. Lett. 1994, 1857-1860
118. K. Ito, M. Yoshitake, T. Katsuki, Heterocycles 1996, 42, 305-317
119. K. Ito, M. Yoshitake, T. Katsuki, Chem. Lett. 1995, 1027-1028
120. K. Ito, T. Fukuda, T. Katsuki, Synlett 1997, 387-389
121. K. Ito, T. Fukuda, T. Katsuki, Heterocycles 1997, 46, 401-411.
122. M. M.-C. Lo, G. C. Fu, Tetrahedron 2001, 57, 2621-2634.
123. Magnin et al. reported the protection of an α-(acylamino)nitrile from hydrolysis by introduction of sterick bulk in the aminonitrile part:, D. R. Magnin, J. A. Robl, R. B. Sulsky, D. J. Augeri, Y. T. Huang, L. M. Simpkins, P. C. Taunk, D. A. Betebenner, J. G. Robertson, B. E. Abboa-Offei, A. Y. Wang, M. Cap, L. Xin, L. Tao, D. F. Sitkoff, M. F. Malley, J. Z. Gougoutas, A. Khanna, Q. Huang, S. P. Han, R. A. Parker, L. G. Hamann, J. Med. Chem. 2004, 47, 2587-2598
124. for an example, where an imidazoline is protected from hydrolyis by bulky substituents, see, M. von Rauch, M. Schlenk, R. Gust, J. Med. Chem. 2004, 47, 915-927.
125. P. M. Manoury, J. L. Binet, J. Rousseau, F. M. Lefevreborg, I. G. Cavero, J. Med. Chem. 1987, 30, 1003-1011
126. for an example where steric bulk reduced susceptibility towards imide cleavage, see, A. D. Borthwick, D. E. Davies, P. F. Ertl, A. M. Exall, T. M. Haley, G. J. Hart, D. L. Jackson, N. R. Parry, A. Patikis, N. Trivedi, G. G. Weingarten, J. M. Woolven, J. Med. Chem. 2003, 46, 4428-4449
127. addition of steric bulk can help to reduce glucuronidation (phase II metabolism):, P. Madsen, A. Ling, M. Plewe, C. K. Sams, L. B. Knudsen, U. G. Sidelmann, L. Ynddal, C. L. Brand, B. Andersen, D. Murphy, M. Teng, L. Truesdale, D. Kiel, J. May, A. Kuki, S. H. Shi, M. D. Johnson, K. A. Teston, J. Feng, J. Lakis, K. Anderes, V. Gregor, J. Lau, J. Med. Chem. 2002, 45, 5755-5775.
128. For examples, see
129. J. L. Duffy, T. A. Rano, N. J. Kevin, K. T. Chapman, W. A. Schleif, D. B. Olsen, M. Stahlhut, C. A. Rutkowski, L. C. Kuo, L. X. Jin, J. H. Lin, E. A. Emini, J. R. Tata, Bioorg. Med. Chem. Lett. 2003, 13, 2569-2572
130. S. Ahmad, L. M. Doweyko, S. Dugar, N. Grazier, K. Ngu, S. C. Wu, K. J. Yost, B. C. Chen, J. Z. Gougoutas, J. D. DiMarco, S. J. Lan, B. J. Gavin, A. Y. Chen, C. R. Dorso, R. Serafino, M. Kirby, K. S. Atwal, J. Med. Chem. 2001, 44, 3302-3310.
131. For the proposed evolutionary origin of the preference of P450 enzymes for lipophilic molecules, see, F. J. Gonzalez, D. W. Nebert, Trends Genet. 1990, 6, 182-186. For quantitative correlation of metabolic stability with lipophilicity, see
132. B. Testa, P. Crivori, M. Reist, P. A. Carrupt, Perspect. Drug Discovery Des. 2000, 19, 179-211
133. K. A. S. Algailany, J. B. Houston, J. W. Bridges, Biochem. Pharmacol. 1978, 27, 783-788
134. A. L. Upthagrove, W. L. Nelson, Drug Metab. Dispos. 2001, 29, 1377-1388.
135. R. B. Bambal, R. P. Hanzlik, Arch. Biochem. Biophys. 1996, 334, 59-66.
136. J. C. Moore, R. Battino, T. R. Rettich, Y. P. Handa, E. Wilhelm, J. Chem. Eng. Data 1982, 27, 22-24
137. J. T. Edward, P. G. Farrell, F. Shahidi, J. Chem. Soc. Faraday Trans. 1 1977, 73, 705-714.
138. For a broader discussion of biotransformation reactions, see, J. Magdalou, S. Fournel-Gigleux, B. Testa, M. Ouzzine, M. Nencki, in Practice of Medicinal Chemistry, Academic Press, London, 2 nd ed., 2003, pp. 517-543.
139. H. T. Gier, S. Searles, J. Med. Pharm. Chem. 1959, 1, 355-363
140. Zarudii et al. found a variety of 3,3-disubstituted oxetanes to possess broncholytic activity in cats:, F. S. Zarudii, D. N. Lazareva, E. S. Kurmaeva, O. B. Chalova, T. K. Kiladze, E. A. Kantor, D. L. Rakhmankulov, Pharm. Chem. J. 1985, 19, 108-111.
141. E. I. EgerII, D. Lemal, M. J. Laster, M. Liao, K. Jankowska, A. Raghavanpillai, A. V. Popov, Y. Gan, Y. Lou, Anesth. Analg. 2007, 104, 1090-1097.
142. P. I. Pradeepkumar, J. Chattopadhyaya, J. Chem. Soc. Perkin Trans. 2 2001, 2074-2083
143. P. I. Pradeepkumar, N. V. Amirkhanov, J. Chattopadhyaya, Org. Biomol. Chem. 2003, 1, 81-92.
144. S. H. Rosenberg, K. P. Spina, H. Stein, J. Cohen, W. R. Baker, H. D. Kleinert, Bioorg. Med. Chem. 1994, 2, 927-937. Despite the high binding affinity the authors state that lack of oral availability and high molecular weight necessitate further development. In the case of carbapenem antibiotics, the replacement of a tetrahydrofuran with an oxetane unit brought no improvement in activity
145. S. M. Sakya, T. W. Strohmeyer, P. Bitha, S. A. Lang, Y. I. Lin, Bioorg. Med. Chem. Lett. 1997, 7, 1805-1810).
146. S. Thaisrivongs, D. T. Pals, L. T. Kroll, S. R. Turner, F. S. Han, J. Med. Chem. 1987, 30, 976-982. For a review about different transition-state mimics of renin, see
147. W. J. Greenlee, Med. Res. Rev. 1990, 10, 173-236.
148. A. K. H. Hirsch, M. S. Alphey, S. Lauw, M. Seet, L. Barandun, W. Eisenreich, F. Rohdich, W. N. Hunter, A. Bacher, F. Diederich, Org. Biomol. Chem. 2008, 6, 2719-2730.